These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Proteasome inhibition by bortezomib: effect on HLA-antibody levels and specificity in sensitized patients awaiting renal allograft transplantation. Guthoff M; Schmid-Horch B; Weisel KC; Häring HU; Königsrainer A; Heyne N Transpl Immunol; 2012 Jun; 26(4):171-5. PubMed ID: 22326708 [TBL] [Abstract][Full Text] [Related]
6. Proteasome inhibition for antibody-mediated rejection. Everly JJ; Walsh RC; Alloway RR; Woodle ES Curr Opin Organ Transplant; 2009 Dec; 14(6):662-6. PubMed ID: 19667989 [TBL] [Abstract][Full Text] [Related]
7. Antihumoral rejection therapy by proteasome inhibitor bortezomib: a case series. Lachmann N; Schütz M; Budde K; Schönemann C; Waiser J Clin Transpl; 2009; ():351-8. PubMed ID: 20527073 [TBL] [Abstract][Full Text] [Related]
8. Case presentations on two patients who received bortezomib for antibody mediated rejection at BIDMC. Pavlakis M Clin Transpl; 2009; ():343-5. PubMed ID: 20524296 [TBL] [Abstract][Full Text] [Related]
9. The fate of anti-HLA antibody among renal transplantation recipients treated with bortezomib. Lonze BE; Dagher NN; Simpkins CE; Singer AL; Segev DL; Zachary AA; Montgomery RA Clin Transpl; 2009; ():377-84. PubMed ID: 20524301 [TBL] [Abstract][Full Text] [Related]
10. Bortezomib rescue in refractory acute humoral rejection--report of a case. Shapiro R; Basu A; Zeevi A; Lunz J; Mapara M; Randhawa P; Morgan C; Tan HP; Sharma V Clin Transpl; 2009; ():431-2. PubMed ID: 20524310 [No Abstract] [Full Text] [Related]
12. Lung transplantation across donor-specific anti-human leukocyte antigen antibodies: utility of bortezomib therapy in early graft dysfunction. Stuckey LJ; Kamoun M; Chan KM Ann Pharmacother; 2012 Jan; 46(1):e2. PubMed ID: 22202499 [TBL] [Abstract][Full Text] [Related]
13. Bortezomib for acute humoral rejection in two repeat transplant recipients. Hardinger KL; Alford K; Murillo D Clin Transpl; 2009; ():479-83. PubMed ID: 20524319 [TBL] [Abstract][Full Text] [Related]
14. Bortezomib alone fails to decrease donor specific anti-HLA antibodies: 4 case reports. Sberro-Soussan R; Zuber J; Suberbielle-Boissel C; Legendre C Clin Transpl; 2009; ():433-8. PubMed ID: 20524311 [TBL] [Abstract][Full Text] [Related]
16. Acute rejection in a highly sensitized lung transplant recipient with pre-formed donor-directed anti-HLA class II antibodies: role of bortezomib therapy. Stuckey LJ; Kamoun M; Wadhwa A; Samaniego M; Bartos C; Berry J; Mahidhara R; Chang AC; Chan KM Clin Transpl; 2009; ():471-4. PubMed ID: 20524317 [No Abstract] [Full Text] [Related]
17. Impact of human leukocyte antigen matching and recipients' panel reactive antibodies on two-year outcome in presensitized renal allograft recipients. Meng HL; Jin XB; Li XT; Wang HW; Lü JJ Chin Med J (Engl); 2009 Feb; 122(4):420-6. PubMed ID: 19302748 [TBL] [Abstract][Full Text] [Related]
19. Determinants of the complement-fixing ability of recipient presensitization against HLA antigens. Bartel G; Wahrmann M; Exner M; Regele H; Schillinger M; Hörl WH; Böhmig GA Transplantation; 2007 Mar; 83(6):727-33. PubMed ID: 17414705 [TBL] [Abstract][Full Text] [Related]
20. The influence of bortezomib on donor specific antibody reduction in patients with antibody mediated rejection. Hardinger KL; Murillo D Clin Transpl; 2011; ():401-8. PubMed ID: 22755438 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]